BioreclamationIVT said today it has acquired TransCell Science for an undisclosed price in a deal designed to broaden the buyer’s expertise and offerings in cell culture and cell-based assays.

TransCell is a CRO specializing in the use of primary cells for phenotypic screening assays. The company says it offers expertise in cell assays, primary cells, stem cells, and cell analysis.

According to its website, TransCell’s clients include “top 10 pharmaceutical and biotech companies, multinational personal care products and cosmetics brands, leading academic institutions, and the National Institutes of Health.”

BioreclamationIVT specializes in control and disease-state matrices manufactured from human and animal biological specimens, and has recently expanded its offerings to include cell processing and phenotypic screening services. The company was established in 1990 and is based in Westbury, NY.

BioreclamationIVT and TransCell are both privately held.

“Building upon our collective synergies, this transaction positions us to accelerate growth and unleash the full potential of our merged companies,” BioreclamationIVT CEO Jeff Gatz said in a statement. “Together, BioreclamationIVT and TransCell Science will form a complete solution spanning biospecimen acquisition to use of those samples within highly relevant in vitro assays.”

Founded in 2011, TransCell has its labs are located at the Harlem Biospace, a New York biotech incubator developed with financial support from the public-private New York City Economic Development Corporation (NYCEDC).

“We have capitalized on growing pressure within the industry to outsource research activities, and I am particularly eager to extend our momentum through this transaction,” stated Chris Hansis, M.D., Ph.D., TransCell’s founder and CEO, who will join BioreclamationIVT as CSO.

BioreclamationIVT is backed by Arsenal Capital Partners, an investor in healthcare and life sciences companies with approximately $3 billion of capital under management.

“TransCell Science aligns with Arsenal's focused M&A program targeting leaders in biological products and complementary services,” added BioreclamationIVT chairman David Spaight, who is also an operating partner of Arsenal Capital.

Previous articleBeyondSpring Aims to Raise $54.31M through IPO and Private Placement
Next articleThe Protein Is Quicker Than the Eye, but Not the AFM